Drug Research
FDA Under Pressure To Alter Accelerated Approval Program
The necessity to update and alter the FDA's now-contentious rapid approval strategy is highlighted by the protracted, complicated FDA process to discontinue commercialization of medications that do not demonstrate safety and efficacy in mandated post-approval confirmatory studies. Over the...
Drug Research
Less Prostate Cancer Testing Leads To More Advanced Tumours
According to data from the U.S. Department of Veterans Affairs (VA), a reduction in prostate cancer screening has been associated with a subsequent rise in advanced malignancies. These findings may prompt a review of the country's current testing recommendations....
Drug Research
Scientists At ICR Research Cancer Response To New Treatments
Researchers discovered that by turning off the function of two genes, stomach tumours can become resistant to ATR inhibitors. As a result, genetic screening tests may one day be used to identify patients with cancers that are most likely...
Drug Research
CDC Suggests Pairing Novavax COVID Shot With Pfizer, Moderna
The Centers for Disease Control and Prevention on October 19Â advised adults in the United States to take Covid boosters from Novavax, even those who had received their primary round of doses from Pfizer, Moderna, or Johnson & Johnson.
Adults 18...
Drug Research
FDA To Fund $38 Million To Fuel 4-Year Rare Disease Research
A total of $38 million has been granted by the US Food and Drug Administration (FDA) in the form of 19 new grants and two new contracts to support the forthcoming four years of clinical trial trials and regulatory...
Drug Research
US-Supplied Ebola Antibodies And Antivirals Reach Uganda
Remdesivir from Gilead Sciences and MBP134, an experimental Ebola antibody drug from Mapp Biopharmaceutical Inc., were sent by the United States last week, ending October 15th, to Uganda to help protect healthcare workers reacting to an outbreak that has...
Drug Research
US Healthcare Saves $21 Billion From Biosimilar Rivalry
Amgen's market forecast for 2022 explains how competition has led to healthcare cost savings and predicts that a sizable proportion of biologics will compete with biosimilars in five to ten years.
The statistics showed that adoption in the US has...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.